PFI-TT: Immuno-Dx: A Biomedical Platform Technology for Personalized Diagnostics

PFI-TT：Immuno-Dx：用于个性化诊断的生物医学平台技术

• 批准号: 2329761
• 负责人: Umer Hassan
• 金额: $ 55万
• 依托单位: Rutgers University New Brunswick
• 依托单位国家: 美国
• 项目类别: Continuing Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2329761&HistoricalAwards=false
• 关键词: PFI; TT; Immuno; Dx; Biomedical

The broader impact/commercial potential of this Partnerships for Innovation - Technology Translation (PFI-TT) project is on developing a biomedical device capable of detecting and monitoring patient's ability to combat infections. The proposed technology addresses the unmet need in emergency department settings of the hospitals where it can be used to monitor patients’ response to therapeutic treatments and identify high-risk patients. A minimal viable prototype (MVP) will be developed from proof-of-concept biosensing technology (called Immuno-Dx), which is centered around monitoring natural ability of blood cells to kill pathogens. Immuno-Dx can have applications in areas (i) to better understand immune system responses of patients to pathogenic infections, (ii) to develop new immunotherapy drugs by pharmaceutical companies, and (iii) to strategize patient treatments by physicians. Biosensing device will be able to provide information regarding patients’ ability to combat infection within 30 min from a drop of whole blood. This PFI-TT project will enable workforce development in spirit with the NSF mission of training next generation of scientists and engineers in technical and entrepreneurial skills, while creating a direct impact on national healthcare and aiding the US economy. The proposed project’ primary objective is to develop an MVP with integrated electronics, data processing, user interface, and onchip sample processing to perform the phagocytosis assay within 30 min from a drop of whole blood. Value proposition of proposed technology lies in its ability to provide vital information about patients’ immune response to infections and therapeutics, to fulfil unmet need for personalized monitoring of patients in emergency department settings of the hospitals. The key innovative features include automated sensing of patient’s ability to combat infections from a drop of whole blood within 30 min, integration of machine learning (ML) models for improved accuracy, automation of manual sample processing steps, and developing a user-inspired 3D printed reader with integrated electronics, data processing and touch controlled user interface. Current key attributes and value proposition of Immuno-Dx can also be leveraged in other areas e.g., infectious diseases, autoimmune disorders, and cancer and can be used by researchers, pharmaceutical companies, clinicians, healthcare providers, and biotech companies. The potential outcome of PFI-TT proposal will be the transition of Immuno-Dx technology from investigator research laboratory to a commercial startup company.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该创新合作伙伴关系 - 技术转化 (PFI-TT) 项目的更广泛影响/商业潜力在于开发一种能够检测和监测患者抵抗感染能力的生物医学设备。所提议的技术解决了急诊科环境中未满足的需求。医院将利用概念验证生物传感技术（称为Immuno-Dx）开发最小可行原型（MVP），该技术可用于监测患者对治疗的反应并识别高风险患者。围绕监测血细胞杀死病原体的自然能力，Immuno-Dx 可应用于以下领域：(i) 更好地了解患者对病原体感染的免疫系统反应，(ii) 制药公司开发新的免疫治疗药物，以及 (iii)生物传感设备将能够在 30 分钟内通过一滴全血提供有关患者抵抗感染能力的信息，以实现 NSF 下一步培训任务的劳动力发展。的一代该项目的主要目标是开发具有集成电子、数据处理、用户界面和片上样本处理功能的 MVP。所提出的技术的价值主张在于其能够在 30 分钟内对一滴全血进行吞噬测定，提供有关患者对感染和治疗的免疫反应的重要信息，以满足急诊科环境中对患者进行个性化监测的未满足的需求。医院。创新的关键功能包括自动感应患者在 30 分钟内抵抗一滴全血感染的能力、集成机器学习 (ML) 模型以提高准确性、手动样本处理步骤的自动化以及开发受用户启发的 3D 打印具有集成电子、数据处理和触摸控制用户界面的读取器，Immuno-Dx 目前的关键属性和价值主张也可用于其他领域，例如传染病、自身免疫性疾病和癌症，可供研究人员、制药公司、信徒， PFI-TT 提案的潜在结果将是将Immuno-Dx 技术从研究者研究实验室转变为商业初创公司。该奖项反映了 NSF 的法定使命，并通过使用评估被认为值得支持。基金会的智力价值和更广泛的影响审查标准。